Cargando…
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
INTRODUCTION: The glucagon-like peptide-1 receptor analogue (GLP-1RA) semaglutide is associated with improvements in glycaemia and cardiovascular risk factors in clinical trials. The aim of this study was to examine the real-world impact of semaglutide administered by injection in people with type 2...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872110/ https://www.ncbi.nlm.nih.gov/pubmed/33565043 http://dx.doi.org/10.1007/s13300-021-01015-z |
_version_ | 1783649137872338944 |
---|---|
author | Williams, David M. Ruslan, Aliya M. Khan, Rahim Vijayasingam, Daneeshanan Iqbal, Fizzah Shaikh, Ayesha Lim, Jia Chudleigh, Richard Peter, Rajesh Udiawar, Maneesh Bain, Stephen C. Stephens, Jeffrey W. Min, Thinzar |
author_facet | Williams, David M. Ruslan, Aliya M. Khan, Rahim Vijayasingam, Daneeshanan Iqbal, Fizzah Shaikh, Ayesha Lim, Jia Chudleigh, Richard Peter, Rajesh Udiawar, Maneesh Bain, Stephen C. Stephens, Jeffrey W. Min, Thinzar |
author_sort | Williams, David M. |
collection | PubMed |
description | INTRODUCTION: The glucagon-like peptide-1 receptor analogue (GLP-1RA) semaglutide is associated with improvements in glycaemia and cardiovascular risk factors in clinical trials. The aim of this study was to examine the real-world impact of semaglutide administered by injection in people with type 2 diabetes (T2D) across three secondary care sites in Wales. METHODS: A retrospective evaluation of 189 patients with T2D initiated on semaglutide between January 2019 and June 2020 with at least one follow-up visit was undertaken. RESULTS: At baseline, participants had a mean age of 61.1 years, mean glycated haemoglobin (HbA1c) of 77.8 mmol/mol (9.3%) and mean body weight of 101.8 kg. At 6 and 12 months of follow-up, mean HbA1c reductions of 13.3 mmol/mol (1.2%) and 16.4 mmol/mol (1.5%), respectively, were observed, and mean weight loss at 6 months was 3.0 kg (all p < 0.001). At 12 months, there were significant reductions in total cholesterol (0.5 mmol/L) and alanine transaminase (4.8 IU/L). Patients naïve to GLP-1RAs or with higher baseline HbA1c at baseline had greater glycaemic reductions, although clinically significant HbA1c reductions were also observed in those who switched from other GLP-1RAs, whose body mass index was < 35.0 and > 35.0 kg/m(2) or who had lower baseline HbA1c. Semaglutide was generally well tolerated, although adverse-effects limited use in 18 patients (9.5%). CONCLUSION: Semaglutide provided clinically and statistically significant reductions in HbA1c, body weight, lipids and liver enzymes. |
format | Online Article Text |
id | pubmed-7872110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-78721102021-02-10 Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study Williams, David M. Ruslan, Aliya M. Khan, Rahim Vijayasingam, Daneeshanan Iqbal, Fizzah Shaikh, Ayesha Lim, Jia Chudleigh, Richard Peter, Rajesh Udiawar, Maneesh Bain, Stephen C. Stephens, Jeffrey W. Min, Thinzar Diabetes Ther Original Research INTRODUCTION: The glucagon-like peptide-1 receptor analogue (GLP-1RA) semaglutide is associated with improvements in glycaemia and cardiovascular risk factors in clinical trials. The aim of this study was to examine the real-world impact of semaglutide administered by injection in people with type 2 diabetes (T2D) across three secondary care sites in Wales. METHODS: A retrospective evaluation of 189 patients with T2D initiated on semaglutide between January 2019 and June 2020 with at least one follow-up visit was undertaken. RESULTS: At baseline, participants had a mean age of 61.1 years, mean glycated haemoglobin (HbA1c) of 77.8 mmol/mol (9.3%) and mean body weight of 101.8 kg. At 6 and 12 months of follow-up, mean HbA1c reductions of 13.3 mmol/mol (1.2%) and 16.4 mmol/mol (1.5%), respectively, were observed, and mean weight loss at 6 months was 3.0 kg (all p < 0.001). At 12 months, there were significant reductions in total cholesterol (0.5 mmol/L) and alanine transaminase (4.8 IU/L). Patients naïve to GLP-1RAs or with higher baseline HbA1c at baseline had greater glycaemic reductions, although clinically significant HbA1c reductions were also observed in those who switched from other GLP-1RAs, whose body mass index was < 35.0 and > 35.0 kg/m(2) or who had lower baseline HbA1c. Semaglutide was generally well tolerated, although adverse-effects limited use in 18 patients (9.5%). CONCLUSION: Semaglutide provided clinically and statistically significant reductions in HbA1c, body weight, lipids and liver enzymes. Springer Healthcare 2021-02-09 2021-03 /pmc/articles/PMC7872110/ /pubmed/33565043 http://dx.doi.org/10.1007/s13300-021-01015-z Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Williams, David M. Ruslan, Aliya M. Khan, Rahim Vijayasingam, Daneeshanan Iqbal, Fizzah Shaikh, Ayesha Lim, Jia Chudleigh, Richard Peter, Rajesh Udiawar, Maneesh Bain, Stephen C. Stephens, Jeffrey W. Min, Thinzar Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study |
title | Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study |
title_full | Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study |
title_fullStr | Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study |
title_full_unstemmed | Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study |
title_short | Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study |
title_sort | real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872110/ https://www.ncbi.nlm.nih.gov/pubmed/33565043 http://dx.doi.org/10.1007/s13300-021-01015-z |
work_keys_str_mv | AT williamsdavidm realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT ruslanaliyam realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT khanrahim realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT vijayasingamdaneeshanan realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT iqbalfizzah realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT shaikhayesha realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT limjia realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT chudleighrichard realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT peterrajesh realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT udiawarmaneesh realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT bainstephenc realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT stephensjeffreyw realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy AT minthinzar realworldclinicalexperienceofsemaglutideinsecondarycarediabetesaretrospectiveobservationalstudy |